Women with Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity: A Pathophysiological Link Between Inflammation and Impaired Insulin Sensitivity?

Abstract

Background and Aim:

Polycystic ovary syndrome (PCOS) is characterized by insulin resistance. Chronic low grade inflammation has been reported to participate in the pathogenesis of insulin resistance. Chitotriosidase (ChT), a protein secreted by activated macrophages, has been shown to be involved in chronic inflammatory responses. In the present study, serum chitotriosidase activity and its relationship with insulin resistance were determined in patients with PCOS.

Methods:

34 patients with PCOS and 44 age and body mass index (BMI) matched healthy controls were enrolled in the study. ChT activity was measured by the fluorescence method. High sensitivity C reactive protein (hs-CRP) and adiponectin levels were determined by enzyme immunoassay (EIA). Insulin resistance was calculated by the homeostasis model assessment of insulin resistance (HOMA-IR) formula.

Results:

Plasma ChT activity, hs-CRP level and HOMA-IR score were significantly higher (p=0.024, p=0.002, p=0.001, respectively) while plasma adiponectin concentration was significantly lower (p=0.018) in women with PCOS compared to healthy controls. Blood ChT activity correlated positively with age, waist-to-hip ratio (WHR), BMI, hs-CRP, HOMA-IR and negatively with blood adiponectin level. After adjustment for age and BMI, ChT activity, total testosterone level and WHR remained as the independent predictors of HOMA-IR score in logistic regression analysis.

Conclusion:

ChT activity is increased in patients with PCOS in concordance with insulin resistance. These findings may reflect the pronounced risk for metabolic syndrome and atherosclerotic diseases in this particular patient group.

Key words

polycystic ovary syndrome - chitotriosidase activity - inflammation - insulin resistance

• References

• 1 Aerts JM, Ottenhoff R, Powlson AS et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 2007; 56: 1341-1349
• 2 Andersson CX, Gustafson B, Hammarstedt A et al. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev 2008; 24: 595-603
• 3 Bloomgarden ZT. Inflammation and insulin resistance. Diabetes Care 2003; 26: 1922-1926
• 4 Boot RG, Renkema GH, Strijland A et al. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995; 270: 26252-26256
• 5 Bourlier V, Bouloumie A. Role of macrophage tissue infiltration in obesity and insulin resistance. Diabetes Metab 2009; 35: 251-260
• 6 Brinkman J, Wijburg FA, Hollak CE et al. Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease. J Inherit Metab Dis 2005; 28: 13-20
• 7 Canudas J, Cenarro A, Civeira F et al. Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate. Metabolism 2001; 50: 447-450
• 8 Corssmit EP, Hollak CE, Endert E et al. Increased basal glucose production in type 1 Gaucher’s disease. J Clin Endocrinol Metab 1995; 80: 2653-2657
• 9 Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 942-947
• 10 Ghauharali-van der Vlugt K, Langeveld M, Poppema A et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 2008; 389: 109-113
• 11 Goodarzi MO, Erickson S, Port SC et al. beta-Cell function: a key pathological determinant in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 310-315
• 12 Guo Y, He W, Boer AM et al. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 1995; 18: 717-722
• 13 Hahn S, Tan S, Sack S et al. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2007; 115: 130-135
• 14 Hollak CE, Vanweely S, Van Oers MH et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994; 93: 1288-1292
• 15 Holmäng A, Svedberg J, Jennische E et al. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 1990; 259: 555-560
• 16 Holte J, Bergh T, Berne C et al. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994; 78: 1052-1058
• 17 Kurt I, Abasli D, Cihan M et al. Chitotriosidase levels in healthy elderly subjects. Ann N Y Acad Sci 2007; 1100: 185-188
• 18 Langeveld M, Ghauharali KJ, Sauerwein HP et al. Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab 2008; 93: 845-851
• 19 Langeveld M, Scheij S, Dubbelhuis P et al. Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia. Metabolism 2007; 56: 314-319
• 20 Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141-154
• 21 Liu S, Navarro G, Mauvais-Jarvis F. Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PLoS One 2010; 5: 11302
• 22 Malaguarnera L. Chitotriosidase: the yin and yang. Cell Mol Life Sci 2006; 63: 3018-3029
• 23 Nilsson O, Månsson JE, Håkansson G et al. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher’s disease. Biochim Biophys Acta 1982; 14: 453-463
• 24 O’Meara NM, Blackman JD, Ehrmann DA et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76: 1241-1247
• 25 Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
• 26 Saito M, Rosenberg A. The fate of glucosylceramide (glucocerebroside) in genetically impaired (lysosomal beta-glucosidase deficient) Gaucher disease diploid human fibroblasts. J Biol Chem 1985; 260: 2295-2300
• 27 Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm 2010; 2010: 758656
• 28 Sonmez A, Haymana C, Tapan S et al. Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. Endocrine 2010; 37: 455-459
• 29 Tagami S, Inokuchi JiJ, Kabayama K et al. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem 2002; 277: 3085-3092
• 30 Yamashita T, Hashiramoto A, Haluzik M et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci USA 2003; 100: 3445-3449
• 31 Yew NS, Zhao H, Hong EG et al. Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One 2010; 21: 11239
• 32 Zhao H, Przybylska M, Wu IH et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 2007; 56: 1210-1218